Xilio Therapeutics Inc (NAS:XLO)
$ 1.02 -0.02 (-1.92%) Market Cap: 44.84 Mil Enterprise Value: -7.13 Mil PE Ratio: 0 PB Ratio: 2.18 GF Score: 27/100

Xilio Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 11, 2023 / 06:55PM GMT
Release Date Price: $2.5 (-6.54%)
Michael Eric Ulz
Morgan Stanley, Research Division - Equity Analyst

Good afternoon, everyone. Thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Mike Ulz, one of the biotech analysts here, and it's my pleasure to introduce Rene Russo, CEO of Xilio Therapeutics. Just a reminder, the format for today is a fireside chat. So if anyone has a question from the audience, please feel free to raise your hand, and we'll be sure to address your question.

Before we get started, I just need to read a quick disclosure for important disclosures. Please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. And with that, thanks, Rene, for joining us.

Questions & Answers

Michael Eric Ulz
Morgan Stanley, Research Division - Equity Analyst

And I thought maybe we could just start with a macro question. If we look

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot